Palladium(II) and platinum(II) complexes with nucleobases and nucleosides. Crystal structure of trans-bis(adeninato)bis(tri-n-butylphosphine)palladium(II)

Synthesis and spectroscopic characterization study of new palladium complexes containing bioactive O,O-chelated ligands: evaluation of the DNA/protein BSA interaction, in vitro antitumoural activity and molecular docking

[Pd{(C,N)-C₆H₄CH₂NH(Et) (Qu)] (2) and [Pd{(C,N)-C₆H₄CH₂NH(Et) (Nar)] (3) (Qu = Quercetin, Nar = Naringin) mononuclear palladium (II) complexes have been synthesized and characterized using elemental analysis, IR and electronic spectroscopy. The interaction of the prepared complexes with calf thymus DNA and bovine serum albumin (BSA), monitored by UV-visible and fluorescence titrations, respectively, have been carried out to better understand the mode of their action under biological conditions. Intercalative binding mode between the complexes and DNA is suggested by the binding constant (K_b) values of 2.5 × 10⁶ and 3.2 × 10⁶ for complexes 2 and 3, respectively. In particular, the in vitro cytotoxicity of the complexes on two cancer cells lines (bladder carcinoma TCC and breast cancer MCF7) showed that the compounds had broad spectrum, anti-cancer activity with low IC₅₀ values and the order of in vitro anticancer activities is consistent with the DNA-binding affinities. In the meantime, the quenching of tryptophan emission with the addition of complexes using BSA as a model protein indicated the protein binding ability. The quenching mechanisms of BSA by the complexes were static processes, according to the results obtained. The competitive binding using Warfarin, Digoxin and Ibuprofen site markers, which contain definite biding sites, demonstrated that the complexes bind to site I on BSA. Ultimately, the binding sites of DNA and BSA with the complexes have been determined by molecular modelling studies.

Design and synthesis of a novel trinuclear palladium(ii) complex containing an oxime chelate ligand: determining the interaction mechanism with the DNA groove and BSA site I by spectroscopic and molecular dynamics simulation approaches

The trinuclear Pd(II) complex containing an oxime ligand showed significant interaction with both CT-DNA and BSA.

Synthesis, crystal structure, DNA-binding and cytotoxicity in vitro of novel cis-Pt(II) and trans-Pd(II) pyridine carboxamide complexes

In an attempt to establish fundamental structure-activity relationships (SAR) of Pt/Pd-based anti-tumour compounds, we have recently designed monodentate pyridyl amide ligand containing central amide units which possess external metal co-ordinating pyridyl group and internal amide functionality. It was prepared in one step from commercially available compounds in moderate to good yield. Surprisingly, treatment of K(2)[MCl(4)] [M=Pt(II), Pd(II)] with ligand N-(4-chlorophenyl)-3-pyridinecarboxamide (L) in the same reaction condition affords two different hydrogen-bonded polymers: cis-[PtL(2)Cl(2)]·CH(3)OH·DMF (1) and trans-[PdL(2)Cl(2)]·2DMF (2). Fluorescence analysis indicates that the two complexes can bind to fish sperm DNA (FS-DNA) and gel electrophoresis assay demonstrates the ability of the complexes to cleave the pBR322 plasmid DNA. The two complexes exhibit cytotoxic specificity and significant cancer cell inhibitory rate. Furthermore, cytotoxicity values are higher in the case of cis-Pt(II) complex than trans-Pd(II) complex in four different cancer cell lines.

One-Dimensional Oxalato-Bridged Cu(II), Co(II), and Zn(II) Complexes with Purine and Adenine as Terminal Ligands

The reaction of nucleobases (adenine or purine) with a metallic salt in the presence of potassium oxalate in an aqueous solution yields one-dimensional complexes of formulas [M(mu-ox)(H(2)O)(pur)](n) (pur = purine, ox = oxalato ligand (2-); M = Cu(II) [1], Co(II) [2], and Zn(II) [3]), [Co(mu-ox)(H(2)O)(pur)(0.76)(ade)(0.24)](n)(4) and ([M(mu-ox)(H(2)O)(ade)].2(ade).(H(2)O))(n) (ade = adenine; M = Co(II) [5] and Zn(II) [6]). Their X-ray single-crystal structures, variable-temperature magnetic measurements, thermal behavior, and FT-IR spectroscopy are reported. The complexes 1-4 crystallize in the monoclinic space group P2(1)/a (No. 14) with similar crystallographic parameters. The compounds 5 and 6 are also isomorphous but crystallize in the triclinic space group P (No. 2). All compounds contain one-dimensional chains in which cis-[M(H(2)O)(L)](2+) units are bridged by bis-bidentate oxalato ligands with M(.)M intrachain distances in the range 5.23-5.57 A. In all cases, the metal atoms are six-coordinated by four oxalato oxygen atoms, one water molecule, and one nitrogen atom from a terminal nucleobase, building distorted octahedral MO(4)O(w)N surroundings. The purine ligand is bound to the metal atom through the most basic imidazole N9 atom in 1-4, whereas in 5 and 6 the minor groove site N3 of the adenine nucleobase is the donor atom. The crystal packing of compounds 5 and 6 shows the presence of uncoordinated adenine and water crystallization molecules. The cohesiveness of the supramolecular 3D structure of the compounds is achieved by means of an extensive network of noncovalent interactions (hydrogen bonds and pi-pi stacking interactions). Variable-temperature magnetic susceptibility measurements of the Cu(II) and Co(II) complexes in the range 2-300 K show the occurrence of antiferromagnetic intrachain interactions.

Binding of Amino-Dialkylated Adenines to Rhenium(III) and Rhenium(IV) Centers

Amino-dialkylated adenines R(2)AdH (R = Me, Et) react with ReCl(3)(MeCN)(PPh(3))(2) to form mer,cis-ReCl(3)(R(2)AdH)(2)(PPh(3)) complexes. Attempts to protonate the coordinated adenine with HCl led to the oxidized trans-ReCl(4)(R(2)AdH)(PPh(3)) compounds. In both types of complexes, the purine binds via the N3 site of the six-membered ring and makes an intramolecular N9-H.Cl hydrogen bond with a chloride ligand. A material of composition ReCl(4)(R(2)AdH)(MeCN) was obtained by reacting R(2)AdH with cis-ReCl(4)(MeCN)(2). It turned out to be a ReCl(4)[R(2)AdC(Me)=NH] complex containing a cyclic amidine ligand resulting from the insertion of the acetonitrile C&tbd1;N group in the N9-H bond of the N3-coordinated adenine unit. Crystal structures were determined for one compound of each type: ReCl(3)(Me(2)AdH)(2)(PPh(3)).2C(6)H(5)CH(3), triclinic, P&onemacr;, a = 14.181(2) Å, b = 17.591(3) Å, c = 19.015(5) Å, alpha = 76.66(2) degrees, beta = 86.80(2) degrees, gamma = 87.02(1) degrees, Z = 4, R = 0.0606; ReCl(4)(Me(2)AdH)(PPh(3)), triclinic, P&onemacr;, a = 10.391(4) Å, b = 10.801(5) Å, c = 13.651(6) Å, alpha = 89.64(4) degrees, beta = 83.49(3) degrees, gamma = 65.14(4) degrees, Z = 2, R = 0.0432; ReCl(4)[Me(2)AdC(Me)=NH].C(6)H(6).CH(2)Cl(2), monoclinic, P2(1)/c, a = 13.941(3) Å, b = 13.656(3) Å, c = 12.874(2) Å, beta = 105.47(2) degrees, Z = 4, R = 0.0406. Most of the signals in the (1)H NMR spectra of these paramagnetic species could be assigned.

Complexes of azathioprine, a biologically active mercaptopurine derivative, with Pt(II), Pd(II), Rh(III), Ru(III) and Ag(I)

In order to possibly elucidate the prevailing factors determining the binding sites in the interactions of azathioprine (AZAH), a biologically active 6-mercaptopurine derivative, with the platinum group and other heavy metals, we probed the binding sites of AZAH with Pt(II), Pd(II), Rh(III), Ru(III), and Ag(I) by using 1H and 195Pt NMR, ESR, and IR spectroscopic techniques as well as magnetic susceptibility measurements and mass spectrometry. The altered coordination behavior of AZAH with respect to the parent 6-mercaptopurine, with sulfur no longer being the primary binding site, was ascertained. In the Pt(II), Rh(III), and Ru(III) complexes, 1H NMR data imply coordination of the metal through the N(3) and N(9) positions of the purine ring, while in the case of the Pt(II) compound, 195Pt NMR data further ascertain AZAH binding in a bridging mode through ring nitrogens. As opposed to the aforementioned metals, in the Pd(II) and Ag(I) compounds, 1H NMR data suggest binding via the N(9) position of deprotonated AZAH. Conductivity measurements for all compounds, except for that of Pt(II), showed a nonelectrolyte behavior in solution; the presence of ionic nitrate in the Pt(II) compound was further ascertained by IR spectroscopy. The coordination sphere of the metal in the cases of the Pt(II) and Pd(II) compounds is completed by ammonia and water molecules, respectively, while in those of the Rh(III) and Ru(III) compounds is completed by chloride bridge. For the Ru(III) compound, the latter is confirmed by magnetic susceptibility measurements.

Synthesis, spectroscopic and magnetic resonance studies of mercury (II) and methylmercury (II) complexes of azathioprine, a biologically active mercaptopurine derivative

Synthetic and spectroscopic studies of the Hg(II) and MeHg(II) complexes of azathioprine (AZA), a biologically active 6-mercaptopurine derivative, were undertaken. The altered coordination behavior of AZA with respect to the parent mercaptopurine, with sulfur no longer being the primary donor atom, was confirmed. As concluded by the 1H NMR, 13C NMR, and IR spectroscopic data, Hg(II) binds to the N(9) position of deprotonated AZA, while in the MeHg(II) compound, coordination occurs through the N(3) and N(9) positions of the purine ring. The values of the coupling constants 2J (199Hg-1H), 1J(199Hg-13C) for the MeHg(II) compound further support complexation via nitrogen atoms of the purine. Elemental analyses confirmed the compounds to be Hg(AZA)2 (1) and [(MeHg)2(AZA)](NO3) (2); conductivity measurement values show that 1 is a nonelectrolyte and 2 is a 1:1 electrolyte. Furthermore, the FAB-MS of the compounds confirms direct binding of the metal to the ligand, and in the case of the MeHg(II) compound, the successive loss of one and two MeHg(II) moieties can be clearly observed.